Skip to main content

Table 2 Summary of the pathways identified from three experiments

From: Hepatic inflammation mediated by hepatitis C virus core protein is ameliorated by blocking complement activation

Pathway

P-value

q-value

Experiment Ia

  

   p53 signaling pathway, CCND1 and PCNA

0.0064

0.0362

   small Leucine-rich Proteoglycan(SLRP) molecules, Lum

0.0468

0.1131

   SREBP control of lipid synthesis

0.0236

0.0319

Experiment II b

  

   extrinsic prothrombin activation pathway, F5, F7, Fgb and Fga

0.001

0.004

   intrinsic prothrombin activation pathway, F5, F9, Fgb and Fga

0.0015

0.0151

   fibrinolysis pathway, serpine 1, Fgb and Fga

0.0016

0.0152

   complement pathway

0.0017

0.018

   inactivation of Gsk3 by AKT causes accumulation of b-catenin in alveolar macrophages

0.0024

0.0170

   platelet amyloid precursor protein pathway, F9 and Serpine 1

0.0392

0.1788

   α-synuclein and Parkin-medicated proteolysis in Parkinson disease, Snca

0.0455

0.1788

Experiment III c

  

   alternative complement pathway

0.0127

0.0644

   lectin induced complement pathway

0.0158

0.0209

   classical complement pathway

0.0174

0.0209

   fibronolysis pathway

0.0174

0.0209

   extrinsic prothrombin activation pathway

0.0205

0.0209

   complement pathway

0.0252

0.0214

  1. aArrayXpath revealed 10 elements in 19 Biocarta pathways. Among the 19 pathways, three are significant.
  2. bArrayXpath has identified 29 elements in 44 Biocarta pathways. Among the 44 pathways, seven are significant.
  3. cArrayXpath revealed 2 (C3 and Fgb) elements in 38 Biocarta pathways. Among the 38 pathways, six are significant.